Investing in CRISPR Therapeutics AG (NASDAQ: CRSP) in 2026 places you at the forefront of the genomic medicine revolution. As of March 16, 2026, the company has successfully transitioned from a pure research entity to a commercial-stage powerhouse, bolstered by the global rollout of its first approved therapy, CASGEVY®.
While the stock has experienced significant volatility in early 2026 due to a major capital raise, its fundamental trajectory remains focused on scaling its gene-editing platform. This guide explores the impact of its recent $550 million convertible note offering, its 2026 pipeline milestones, and the strategic outlook for Kiwi investors looking to diversify into high-growth U.S. biotech.
1. Stock Performance: March 2026 Update
As of Monday, March 16, 2026, CRSP stock is trading at approximately US$48.75. The stock faced a sharp ~14% pullback over the last week following the announcement of its upsized convertible debt offering.
Key Financial Metrics (at March 16, 2026)
| Metric | Value | 1-Year Trend |
| Current Price | ~US$48.75 | +35.6% |
| 52-Week Range | $30.06 – $78.48 | High Volatility |
| Market Cap | ~US$4.68 Billion | Mid-Cap Growth |
| Analyst Consensus | Buy | Targets $71 – $82 |
- Recent Momentum: The stock reached a 2026 high of $61.76 in February but retreated in March.
- Fundraising Dip: The March 10 announcement of a debt offering caused a 12% single-day drop, as investors weighed the potential for future shareholder dilution.
Recent Momentum: The stock reached a 2026 high of $61.76 in February but retreated in March.
Fundraising Dip: The March 10 announcement of a debt offering caused a 12% single-day drop, as investors weighed the potential for future shareholder dilution.
2. Major Catalyst: The $550M Strategic Capital Raise
On March 16, 2026, CRISPR Therapeutics is scheduled to close its upsized $550 million convertible senior notes offering (due 2031).
- The Deal: Originally planned for $350M, the deal was upsized due to high institutional demand. The notes carry a conversion price of approximately $76.56 per share (a 45% premium over the March 10 price).
- Purpose: The net proceeds (est. $536M) will be used to fund the aggressive expansion of the clinical pipeline and support the global commercialization of CASGEVY®.
- Balance Sheet: This raise adds to a robust cash position that was already approximately $1.9 billion at the start of the year, providing a "cash runway" of 3–4 years.
The Deal: Originally planned for $350M, the deal was upsized due to high institutional demand. The notes carry a conversion price of approximately $76.56 per share (a 45% premium over the March 10 price).
Purpose: The net proceeds (est. $536M) will be used to fund the aggressive expansion of the clinical pipeline and support the global commercialization of CASGEVY®.
Balance Sheet: This raise adds to a robust cash position that was already approximately $1.9 billion at the start of the year, providing a "cash runway" of 3–4 years.
3. 2026 Pipeline & Strategic Milestones
Workday's primary appeal lies in its dominant market share in large-enterprise HR and financial software. Its business model is built on high-margin, high-retention subscription revenue.
CASGEVY® (Commercial Engine)
- Revenue Growth: CASGEVY exceeded $100M in revenue in 2025. For 2026, analysts expect sales to accelerate toward $270M as treatment centers scale.
- Pediatric Expansion: Regulatory submissions for patients aged 5–11 are expected in the first half of 2026 for both Sickle Cell Disease and Beta Thalassemia.
Revenue Growth: CASGEVY exceeded $100M in revenue in 2025. For 2026, analysts expect sales to accelerate toward $270M as treatment centers scale.
Pediatric Expansion: Regulatory submissions for patients aged 5–11 are expected in the first half of 2026 for both Sickle Cell Disease and Beta Thalassemia.
Next-Gen Clinical Trials
- Autoimmune Diseases: Updates on zugo-cel (formerly CTX112™) for systemic lupus and other autoimmune conditions are expected in H2 2026.
- Cardiovascular: Clinical trials for CTX340 (refractory hypertension) are slated to begin in H1 2026, with CTX310 (Lp(a) program) updates due in the second half of the year.
- Oncology: Continued development of "off-the-shelf" CAR-T therapies to replace complex patient-specific treatments.
Autoimmune Diseases: Updates on zugo-cel (formerly CTX112™) for systemic lupus and other autoimmune conditions are expected in H2 2026.
Cardiovascular: Clinical trials for CTX340 (refractory hypertension) are slated to begin in H1 2026, with CTX310 (Lp(a) program) updates due in the second half of the year.
Oncology: Continued development of "off-the-shelf" CAR-T therapies to replace complex patient-specific treatments.
4. Strategic Outlook for the New Zealand Investor
For Kiwis, CRSP offers a high-beta "pure play" on CRISPR/Cas9 technology. It is a high-risk, high-reward asset that behaves differently than traditional NZ dividend stocks.
Why consider CRISPR Therapeutics now?
Valuation Entry Point: The recent pull-back to the sub-$50 level is viewed by some analysts as an attractive entry point before the next wave of clinical data.
Commercial De-risking: Unlike "pre-revenue" biotechs, CRSP has a proven, approved product on the market.
Currency Diversification: Holding NASDAQ-listed assets in USD can act as a natural hedge if the NZD weakens against the Greenback.
Risks to Monitor
- Execution Risk: Revenue recognition for CASGEVY is complex due to a 60/40 profit split with Vertex Pharmaceuticals.
- High Beta: With a beta of 3.02, the stock moves three times as much as the broader market, making it unsuitable for low-risk portfolios.
- Ongoing Losses: The company remains unprofitable as it prioritizes massive R&D spending.
Execution Risk: Revenue recognition for CASGEVY is complex due to a 60/40 profit split with Vertex Pharmaceuticals.
High Beta: With a beta of 3.02, the stock moves three times as much as the broader market, making it unsuitable for low-risk portfolios.
Ongoing Losses: The company remains unprofitable as it prioritizes massive R&D spending.
5. How to Buy CRSP Stock in New Zealand
Kiwis can access CRISPR Therapeutics through platforms that provide access to the NASDAQ exchange:
- Sharesies: Best for smaller, regular "dollar-cost averaging" (DCA) with fractional shares.
- Hatch: Preferred for larger trades due to its flat-fee structure ($3 USD) and direct ownership model.
- Stake: Known for fast execution and high-quality mobile interface.
Sharesies: Best for smaller, regular "dollar-cost averaging" (DCA) with fractional shares.
Hatch: Preferred for larger trades due to its flat-fee structure ($3 USD) and direct ownership model.
Stake: Known for fast execution and high-quality mobile interface.
Frequently Asked Questions (FAQ)
What is the ticker symbol for CRISPR Therapeutics?
It is listed on the NASDAQ exchange under the ticker symbol CRSP.
Does CRSP pay a dividend?
No. CRISPR Therapeutics is a growth-stage biotechnology company that reinvests all capital into its research pipeline.
Why did the stock drop in March 2026?
The stock fell following the announcement of a $550 million convertible note offering. While this provides cash for growth, it also introduces the potential for future shareholder dilution if the debt is converted into shares.
Is CASGEVY® approved in New Zealand?
While CASGEVY is approved in the US, UK, EU, and Canada, it is not yet widely available in New Zealand. Kiwi patients often monitor progress in Australia and the US for access to these therapies.
What is the 52-week high for CRSP?
The 52-week high is US$78.48, reached in late 2025.
Would you like me to analyze how CRISPR's cash runway compares to other gene-editing rivals like Beam Therapeutics or Intellia?
